New drugs for fibrotic diseases! Bringer ingelham and enleofen have reached a strategic cooperation to develop the first anti-il-11 therapeutic antibody therapy of the same kind!

January 13, 2020 / BIOON / -- Boehringer Ingelheim, a German pharmaceutical company, and enleofen bio PTE Ltd., a Singapore biotechnology company (enleofen) recently announced that bringer Ingelheim has acquired the global exclusive right of enleofen clinical pre-il-11 platform to develop the first-in-class therapy for various fibroinflammatory diseases The new cooperation combines the leading expertise and comprehensive R & D pipeline of bringer Ingelheim in the field of fibrotic diseases, the world's leading expertise of enleofen in the field of IL-11 biology and the company's broad therapeutic antibody targeting the pathway Dr Clive R wood, senior vice president of bringer ingelham and head of global discovery research, said: "the impressive preclinical studies of enleofen reveal the potential of IL-11 blockers in the treatment of a wide range of diseases We are very excited to be able to incorporate these monoclonal antibodies into our R & D pipeline and help many patients whose current therapies cannot meet their needs more quickly " IL-11 is a kind of cytokine, a kind of protein used to communicate by some cells of the body, which plays a key role in the state of fibroinflammation IL-11 blockade has been shown to inhibit diseases in many organs (liver, lung, kidney, retina, intestine, heart and skin) In preclinical studies, antibody based IL-11 antagonists can prevent and reverse inflammation and fibrosis, and repair organ function Enleofen is a company separated from Singapore National Heart Center (NHCs) and Duke NUS Medical School of SingHealth group It belongs to Singapore SingHealth Duke NUS academic medical center (AMC) When it was founded in 2017, AMC transferred a series of patents and multi antibody products to enleofen Since then, enleofen has set up an extensive anti-il-11 antibody platform and pushed its drug development project to the clinic Bringer ingelham will now further develop the platform, and plans to work with AMC scientists to accelerate the platform into clinical development The initial focus will be on new therapies for NASH and ILDs patients (two core disease areas of bringer Ingelheim company) Based on the core role of IL-11 in the disease, it is possible to further expand to fibroinflammatory diseases Professor Stuart cook, director and co-founder of enleofen, said: "as a leader in the research and development field of anti fibrosis treatment, enleofen is very excited to cooperate with it We can work together to further develop anti-il-11 therapy and solve the endless medical needs of patients around the world Preclinical data covering a wide range of diseases are unprecedented, and this new therapy targeting IL-11 may be subversive " The acquisition of enleofen's IL-11 project has strengthened the pipeline product portfolio of bringer Ingelheim, which will combine effective methods and disease-specific methods for a variety of fibrotic diseases to achieve more prominent therapeutic effects, and build on the experience of nedanib in the treatment of fibrotic pulmonary diseases Bringer ingelham will be solely responsible for the licensed treatment options, including clinical, registration and commercial promotion According to the terms of this agreement, enleofen may receive more than US $1 billion in each product's early, successful development and commercialization milestones Enleofen is a biotechnology company based in Singapore, which is committed to the development of first-class antibody therapy drugs for the treatment of human fibroinflammatory diseases Stuart cook and Sebastian Sch ä fer, founders of Singapore's National Heart Center (located in SingHealth and Duke NUS), conducted the initial discovery science and drug target validation, which was then delegated to enleofen, cook as a director Since 2017, with the support of experienced international life science executives and investors, including founding directors Jeffrey Lu and Andrew Khoo, the company has invested heavily in target validation, drug development and preclinical research Boehringer Ingelheim partners with enleofen to develop first-in-class anti-il-11 theories for a range of fibrous diseases